Seviteronel is under clinical development by Innocrin Pharmaceuticals and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Seviteronel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seviteronel overview
Seviteronel (VT-464) is under development for the treatment of metastatic castration-refractory prostate cancer (CRPC), advanced estrogen receptor positive (ER-positive) breast cancer in men or women, triple negative breast cancer and other androgen receptors (AR)-driven cancers. The drug candidate is administered orally as once-daily formulation. It is second-generation molecule and targets CYP17 and androgen receptor. The drug candidate is based on a Metallophile technology platform. The technology develops analogs of known metallo enzyme inhibitors by optimizing the metal-binding component of these small molecule inhibitors.
For a complete picture of Seviteronel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
